Heart-on-a-chip technology predicts preclinical systolic and diastolic in vivo observations for novel cardiac drug in development

(CG Life) MyoKardia presented data at the American Heart Association's annual meeting that showed TARA's heart-on-a-chip system was able to measure in vivo cardiac performance of its Phase 2 cardiac drug candidate.